143 related articles for article (PubMed ID: 12458965)
1. The functioning neuronal transporter for dopamine: kinetic mechanisms and effects of amphetamines, cocaine and methylphenidate.
Schenk JO
Prog Drug Res; 2002; 59():111-31. PubMed ID: 12458965
[TBL] [Abstract][Full Text] [Related]
2. A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate.
Chen R; Han DD; Gu HH
J Neurochem; 2005 Jul; 94(2):352-9. PubMed ID: 15998286
[TBL] [Abstract][Full Text] [Related]
3. Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain.
Volkow ND; Wang GJ; Fowler JS; Fischman M; Foltin R; Abumrad NN; Gatley SJ; Logan J; Wong C; Gifford A; Ding YS; Hitzemann R; Pappas N
Life Sci; 1999; 65(1):PL7-12. PubMed ID: 10403500
[TBL] [Abstract][Full Text] [Related]
4. What can be learned from studies of multisubstrate mechanisms of neuronal dopamine transport?
Schenk JO; George SE; Schumacher PD
Eur J Pharmacol; 2003 Oct; 479(1-3):223-8. PubMed ID: 14612152
[TBL] [Abstract][Full Text] [Related]
5. Dopamine neuronal transport kinetics and effects of amphetamine.
Jones SR; Joseph JD; Barak LS; Caron MG; Wightman RM
J Neurochem; 1999 Dec; 73(6):2406-14. PubMed ID: 10582600
[TBL] [Abstract][Full Text] [Related]
6. The interaction of methylphenidate and benztropine with the dopamine transporter is different than other substrates and ligands.
Dar DE; Mayo C; Uhl GR
Biochem Pharmacol; 2005 Aug; 70(3):461-9. PubMed ID: 15950948
[TBL] [Abstract][Full Text] [Related]
7. Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux.
Wall SC; Gu H; Rudnick G
Mol Pharmacol; 1995 Mar; 47(3):544-50. PubMed ID: 7700252
[TBL] [Abstract][Full Text] [Related]
8. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications.
Volkow ND; Wang GJ; Fowler JS; Logan J; Franceschi D; Maynard L; Ding YS; Gatley SJ; Gifford A; Zhu W; Swanson JM
Synapse; 2002 Mar; 43(3):181-7. PubMed ID: 11793423
[TBL] [Abstract][Full Text] [Related]
9. Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue.
Ukairo OT; Bondi CD; Newman AH; Kulkarni SS; Kozikowski AP; Pan S; Surratt CK
J Pharmacol Exp Ther; 2005 Aug; 314(2):575-83. PubMed ID: 15879005
[TBL] [Abstract][Full Text] [Related]
10. Fluctuation of the dopamine uptake inhibition potency of cocaine, but not amphetamine, at mammalian cells expressing the dopamine transporter.
Ukairo OT; Ramanujapuram S; Surratt CK
Brain Res; 2007 Feb; 1131(1):68-76. PubMed ID: 17169338
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter.
Pifl C; Drobny H; Reither H; Hornykiewicz O; Singer EA
Mol Pharmacol; 1995 Feb; 47(2):368-73. PubMed ID: 7870046
[TBL] [Abstract][Full Text] [Related]
12. Measuring dopamine transporter occupancy by cocaine in vivo: radiotracer considerations.
Fowler JS; Volkow ND; Logan J; Gatley SJ; Pappas N; King P; Ding YS; Wang GJ
Synapse; 1998 Feb; 28(2):111-6. PubMed ID: 9450511
[TBL] [Abstract][Full Text] [Related]
13. Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of "high".
Volkow ND; Wang GJ; Fowler JS; Gatley SJ; Logan J; Ding YS; Dewey SL; Hitzemann R; Gifford AN; Pappas NR
J Pharmacol Exp Ther; 1999 Jan; 288(1):14-20. PubMed ID: 9862747
[TBL] [Abstract][Full Text] [Related]
14. Molecular model of the neural dopamine transporter.
Ravna AW; Sylte I; Dahl SG
J Comput Aided Mol Des; 2003; 17(5-6):367-82. PubMed ID: 14635728
[TBL] [Abstract][Full Text] [Related]
15. Dopamine transporter-dependent induction of C-Fos in HEK cells.
Yatin SM; Miller GM; Norton C; Madras BK
Synapse; 2002 Jul; 45(1):52-65. PubMed ID: 12112414
[TBL] [Abstract][Full Text] [Related]
16. [(11)]Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy.
Fowler JS; Volkow ND; Wang GJ; Gatley SJ; Logan J
Nucl Med Biol; 2001 Jul; 28(5):561-72. PubMed ID: 11516700
[TBL] [Abstract][Full Text] [Related]
17. Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice.
Sora I; Wichems C; Takahashi N; Li XF; Zeng Z; Revay R; Lesch KP; Murphy DL; Uhl GR
Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7699-704. PubMed ID: 9636213
[TBL] [Abstract][Full Text] [Related]
18. Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine.
Izenwasser S; Coy AE; Ladenheim B; Loeloff RJ; Cadet JL; French D
Eur J Pharmacol; 1999 Jun; 373(2-3):187-93. PubMed ID: 10414438
[TBL] [Abstract][Full Text] [Related]
19. Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine.
Kahlig KM; Galli A
Eur J Pharmacol; 2003 Oct; 479(1-3):153-8. PubMed ID: 14612146
[TBL] [Abstract][Full Text] [Related]
20. Dopamine-transporter occupancy after intravenous doses of cocaine and methylphenidate in mice and humans.
Gatley SJ; Volkow ND; Gifford AN; Fowler JS; Dewey SL; Ding YS; Logan J
Psychopharmacology (Berl); 1999 Sep; 146(1):93-100. PubMed ID: 10485970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
